Clinical Trials
8 trialsNCT05797168 2026-06-03
FONTANA
AstraZeneca
Phase 1/2 Recruiting
NCT05566223 2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2 Withdrawn
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT05887492 2025-11-18
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03184571 2025-09-25
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
BerGenBio ASA
Phase 2 Completed
NCT04682431 2024-03-22
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT04691375 2024-03-22
A Study of PY314 in Subjects With Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT04452214 2023-07-14
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
Phase 1 Completed